Zevra Therapeutics is trading 5.3% down at $10.39 on October 1, 2026, with no clear company-specific catalyst identified in the latest company releases.

  • The most recent listed release was September 2 and concerned investor conferences.
  • Major indices were mixed, moving less than 0.5%; available evidence does not establish a market-wide explanation for the drop.
  • Shares also declined 3.26% on September 30; no volume information was provided.